Citius Pharmaceuticals — Investor Briefing (NASDAQ: CTXR)

Report Unlocked

*Issuer-Sponsored Content

Late-Stage Biopharma · Cranford, NJ · May 2026

NASDAQ CTXR Citius Pharmaceuticals, Inc.

They just launched their first FDA-approved drug. Wall Street hasn't caught up yet.

Citius Pharma went from no revenue to $5.6 million in four months at roughly 80% gross margins — and the stock currently trades at a market value of about $11 million. Two more late-stage drugs are in the pipeline.

▸ Full Investor Profile

See the live stock price, filings, and full company report.

See the Full Story →

NASDAQ: CTXR · Live Investor Page

HQ Cranford, NJ LAUNCH LYMPHIR · Dec 2025 PIPELINE 3 Late-Stage

The Story

Three things to know before you look at the chart.

01 One FDA-approved drug, now actually generating money. Citius launched LYMPHIR in December 2025 — an immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma, a rare cancer. In the first four months of sales, the company brought in $5.6 million in revenue at roughly 80% gross margins, with insurance coverage now in place for nearly all U.S. commercial patients.
02 Two more drugs are deep in the pipeline. Mino-Lok targets life-threatening bloodstream infections in cancer patients with catheters — a market the company estimates at $1.8 billion worldwide. Halo-Lido is a prescription hemorrhoid treatment combining a steroid and a numbing agent. Both are in late-stage development.
03 The company is valued at about $11 million. That's the entire publicly-traded market value — for a company with an FDA-approved drug already selling, two more late-stage programs, a 75% ownership stake in NASDAQ-listed Citius Oncology (CTOR), and founders who've personally invested $26.5 million of their own money. That gap between current value and pipeline potential is the entire story — and the entire risk.

Important — Read This

CTXR is a small-cap biotech. The company's most recent SEC filings include a "going concern" disclosure — meaning management has explicitly raised doubt about its ability to continue operating beyond November 2026 without additional financing. The company had $4.6M cash on hand at March 31, 2026 and reported a $37.5M loss for the half-year. Additional stock issuances to raise capital will likely dilute existing shareholders. This stock can lose substantial value, including 100% of its value.

The Pipeline

Three drugs. Three different markets.

LYMPHIR™

FDA Approved · Selling

For adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma — a rare type of blood cancer.

Launched December 2025. $5.6M in net revenue in the first four months at ~80% gross margins. Payer coverage near 100% of U.S. commercial lives; 83% of target oncology accounts on formulary or in active review. Sold through majority-owned subsidiary Citius Oncology (NASDAQ: CTOR).

Mgmt. Initial Market Estimate $400M+ (growing)

Mino-Lok®

Late-Stage Trial Complete

For catheter-related bloodstream infections in cancer patients — life-threatening complications that often force removal of the catheter and disruption of treatment.

Designed to save the catheter and clear the infection without surgery. Phase 3 trial completed. The company is preparing regulatory next steps; FDA approval is not guaranteed and timing is uncertain.

Company-Estimated Worldwide Potential $1.8B

Halo-Lido

Phase 2b

A topical prescription combining a corticosteroid (to reduce inflammation) and lidocaine (to numb pain) for hemorrhoid symptoms.

Targets a condition affecting an estimated 10 million Americans where there is currently no FDA-approved prescription option that combines both anti-inflammatory and pain-relief effects.

Indication Affects ~10M Americans

The Numbers That Matter

The risk and the reward, in one frame.

Current Market Value

~$11M

Pipeline Market Potential

$2B+

This gap is the entire story — and the entire risk. The $2B+ figure combines management's $400M+ estimate for LYMPHIR's initial market with the company's $1.8B estimate for Mino-Lok's worldwide potential. These are total addressable markets, not revenue projections. Capturing any meaningful share takes years, additional capital, and execution that may not happen. The market cap reflects that uncertainty — and the company's going-concern disclosure.

At A Glance

The whole picture, in one frame.

$5.6M

First 4 Months of LYMPHIR Sales

~80%

LYMPHIR Gross Margin

~100%

U.S. Commercial Payer Coverage

Late-Stage Pipeline Programs

$26.5M

Founders' Personal Investment

~$11M

Current Market Capitalization

▸ Your Next Step

The part of the report that matters.

The complete investor page — with the live stock price, SEC filings, pipeline details, and the latest reports — is just one click away.

See the Full Story →

Citius Pharmaceuticals — Q2 FY2026 Financial Results, May 15, 2026. Reports $5.6M LYMPHIR net revenue over four months at ~80% gross margins, payer coverage near 100% of commercial lives, and 83% of target accounts on formulary or in review. PRNewswire
Citius Pharmaceuticals — Q1 FY2026 Financial Results, February 13, 2026. First reported revenue of $3.9M following LYMPHIR launch. PRNewswire
Citius Pharmaceuticals — Form 10-Q for the quarterly period ended March 31, 2026. Includes going-concern disclosure and $4.6M cash position. SEC EDGAR (CTXR 10-Q)
Citius Oncology, Inc. — Subsidiary financial filings (NASDAQ: CTOR). SEC EDGAR (CTOR)
Citius Pharmaceuticals — LYMPHIR product page and labeling. lymphirhcp.com
Citius Pharmaceuticals — Mino-Lok® program page. citiuspharma.com
Citius Pharmaceuticals — Halo-Lido program page. citiuspharma.com
U.S. Food and Drug Administration — LYMPHIR (denileukin diftitox) approval, August 2024.

DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical."

Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we manage an ongoing marketing campaign for Citius Pharmaceuticals, Inc. from which we receive direct compensation.

It might seem obvious, but while our client claims not to own any shares in Citius Pharmaceuticals, Inc., whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Citius Pharmaceuticals, Inc. might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This is especially true for small-cap clinical-stage and early-commercial biopharmaceutical companies. Citius has explicitly disclosed in its most recent SEC filings substantial doubt about its ability to continue as a going concern beyond November 2026 without additional capital. The company had approximately $4.6 million in cash on hand as of March 31, 2026, and is likely to need to raise additional capital through stock issuances that will dilute existing shareholders. The Phase 3 Mino-Lok program and other late-stage assets may not receive FDA approval, may face commercialization delays, or may not achieve the worldwide sales potential referenced on this page. LYMPHIR's continued commercial success depends on manufacturing supply (which the company is currently transitioning to a new contract manufacturer), payer coverage, and physician adoption. Any of these factors could cause shares to lose substantial value, including 100% of their value. You could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's up to you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional investment advisor.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, investment advis0r (IA), or IA rep's with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that's the scoop! If you're intrigued and want to learn more about the company we talk about, hit up the SEC's website to dig into their filings and see the full picture.

See the Full Story → CTXR